Peapod Lane Capital’s MaxCyte MXCT Stock Holding History

Peapod Lane Capital’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.61M	Buy	2,125,752 +793,559	+60%	+$791K	1.76%	21
2026 Q1	$926K	Buy	+1,332,193	New	+$1.24M	0.76%	51

Other funds holding MXCT

CFM

Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Mudita Advisors London, United Kingdom $481M AUM 73.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BFM

Brooklands Fund Management London, United Kingdom $128M AUM

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Peapod Lane Capital's MXCT Position: Q2 2026 in Review

Peapod Lane Capital increased its MaxCyte (MXCT) stake by 60% in Q2 2026, buying an estimated $791K and bringing the position to 2,125,752 shares worth $2.61M. The position accounts for 1.76% of the portfolio, ranked #21.

Peapod Lane Capital first reported a position in MXCT in Q1 2026 and has held it in 2 quarters since. 123 funds tracked by Wall St. Rank hold MXCT as of Q2 2026.

Peapod Lane Capital held 2,125,752 shares of MaxCyte worth $2.61M as of Q2 2026.
Peapod Lane Capital bought 793,559 MaxCyte shares in Q2 2026, an estimated $791K.
MaxCyte made up 1.76% of Peapod Lane Capital's portfolio in Q2 2026, its #21 holding.
Peapod Lane Capital first reported a position in MaxCyte in Q1 2026 and has held it in 2 quarters since.
123 funds tracked by Wall St. Rank held MaxCyte as of Q2 2026.

Based on Peapod Lane Capital's 13F filing for Q2 2026, filed 27 Jul 2026.